The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects — Stella

Home/Depressive Disorder/

View on ClinicalTrials.gov

Recruiting

Back to Depressive Disorder trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

VA Connecticut Healthcare System, West Haven, Connecticut

Key details

Phase

Safety & dosing

Sponsor

Yale University

Collaborators

American Foundation for Suicide Prevention, National Center for PTSD

Enrollment target

~30 participants

Started

April 2023

Primary completion

March 2033

Age range

21 Years – 65 Years

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.